Wave Life Sciences’ Post

Excited to share our latest publication in Nature Reviews Gastroenterology & Hepatology on cell senescence in liver diseases! 🚀🔬 As co-first author, I am thrilled to present our review titled 🔈 "Cell Senescence in Liver Diseases: Pathological Mechanism and Theranostic Opportunity". crafted with my mentor, Jordi Gracia-Sancho, MSc PhD FAASLD, and esteemed colleague David Sanfeliu Redondo. Our review explains how senescent hepatocytes, liver sinusoidal endothelial cells, and hepatic stellate cells play critical roles in liver function and disease progression. From morphological changes to metabolic alterations, we cover the intricate dance between senescence and liver health, and propose potential therapeutic opportunities to target and eliminate harmful senescent cells. #liverhealth #senescence #hepatology #liverdisease https://lnkd.in/dVh32A5u

🔬📈 New Meta-Analysis Alert! 📈🔬 Sarcopenia + MASLD: A pairing no one asked for but science insists on investigating! Our latest meta-analysis dives deep into the connection between muscle loss and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, formerly NAFLD). Turns out, sarcopenia increases the odds of MASLD and liver fibrosis! 😲 🧠 25 studies pooled for a comprehensive look, and the results are in: 📊 Sarcopenia raises the risk of MASLD by 25% (whoa!) 📉 But Skeletal Mass Index (SMI) is like, "Eh, no big deal." 🧬 More muscle, fewer fibrosis worries? Seems like it. Catch the full details online now at Annals of Hepatology! https://lnkd.in/gFfs__AC #LiverHealth #Sarcopenia #MASLD #LiverFibrosis #MedicalResearch #Hepatology

Happy to share our recent review article on “Therapeutic Plasma Exchange in Hepatology: Indications, Techniques & Practical application” in Journal of Clinical & Experimental Hepatology ⭐️ Especially useful all those looking after patients with Liver diseases! 👍 https://lnkd.in/gJW4uYTD

🔍 6x reduction in false positives compared to current clinical guidelines Join us at the upcoming EASL | The Home of Hepatology Congress where we'll present our poster evaluating liver fibrosis screening methods: “Replacing FIB-4 with LiverPRO as an initial test for detecting advanced fibrosis leads to a 6-fold reduction in false positives” Our study compares the traditional FIB-4 index with our LiverPRO tool in a Danish screening cohort of +6000 patients – finding that substituting FIB-4 with LiverPRO enhances classification accuracy by reducing false positives six-fold. But also, confirms the potential of non-invasive tests like LiverPRO to accurately detect Steatotic Liver Disease (SLD) 👏 . Discover more of our results by visiting our poster (# SAT-250) on the 8th of June at EASL Congress 2024. Want to know more or chat about the findings? Reach out to our CSO Katrine Prier Lindvig! Co-authored by: Katrine Prier Lindvig, Maja Thiele, Aleksander Krag, Katrine H Thorhauge, Helle L Schnefeldt, Johanne K Hansen, Camilla D Hansen, Stine Johansen, Peter Andersen, Ida F. Villesen, Katrine Bech, Nikolaj Torp and Mads Israelsen #EASLCongress2024 #EASLposter #datadrivendiagnostics #steatoticliverdisease

Revising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias https://lnkd.in/d73CJPdG Eurotransplant liver transplant candidates are prioritized by Model for End-stage Liver Disease (MELD), a 90-day waitlist survival risk score based on the INR, creatinine and bilirubin. Several studies revised...

SALHN Hepatologist, Professor Alan and his team of SALHN researchers are involved in a landmark study into chronic liver disease care involving researchers from Flinders Medical Centre and Flinders University.   The study, which was published in the esteemed international journal 'Hepatology', provides evidence that improved models of care can benefit patients with decompensated cirrhosis.   This is important as decompensated liver disease is one of the major clinical challenges in Gastroenterology and Hepatology. Nationally, more than 6 million Australians suffer from chronic liver disease, resulting in more than 7000 deaths a year, while obesity-related liver disease is expected to become a modern epidemic by 2050.   The study represents more than five years of work conducting a randomised controlled trial (RCT) led by Professor Alan and his team, with funding support from Flinders University and the National Health and Medical Research Council (NHMRC). The RCT involved six Australian tertiary care hospitals across three states and represents one of the first investigator initiated multicentre RCTs in Australian hepatology.

Investigators concluded that 80mg and 100mg of #resmetirom significantly improved #NASH resolution and liver fibrosis in a clinical trial compared to placebo. The future is bright for #MASLD and #MASH patients. What are you doing NOW to accurately risk-stratify and stage liver disease in your practice? #NAFLD #FattyLiverDisease #FattyLiver #FibroScan #Echosens #LiverHealth #LiverHealthMatters #Fibrosis #Cirrhosis #Gastroenterology #Hepatology https://lnkd.in/e8Q7azdC

In her opening this morning at Global Liver Institute’s A3, Donna Cryer, Board Member and Past President and CEO, emphasizes the importance of being present in the moment and using one's talents to serve and make a difference, drawing inspiration from Maya Angelou's idea of being "of your time." She recounts the story of Regina Holliday, who turned personal tragedy into patient advocacy by using her artistic talents to highlight issues in healthcare, eventually creating a "walking gallery" of jackets telling patients' stories. Donna encourages the attendee advocates to recognize their own talents, creativity, and potential to contribute, emphasizing that it's selfish not to share one's gifts. The speech closes with a call to help others by addressing challenges and making future struggles unthinkable, urging everyone to act in the ways they can to make history. Here are a few key messages from Donna Cryer's speech this morning: 1. Be present and of your time: Drawing from Maya Angelou’s teachings, Cryer highlights the importance of being in the moment and using persistence, creativity, and talent to contribute meaningfully to the world. 2. Turn personal challenges into advocacy: Using Regina Holliday’s story, Cryer emphasizes how personal pain and loss can be transformed into a powerful force for change, as Holliday did by painting advocacy stories on jackets to raise awareness about healthcare failures. 3. Everyone has something to give: Cryer encourages people to recognize their unique talents, noting that it's selfish to withhold them, as each person can contribute in their own way to serve others and address larger societal issues. 4. Help others by making their struggles easier: The goal of advocacy is not only to share stories but also to make future hardships unthinkable by addressing current challenges, ensuring that others don’t have to endure the same difficulties. American Association for the Study of Liver Diseases (AASLD) EASL the home of Hepatology Madrigal Pharmaceuticals Fatty Liver Foundation NASH kNOWledge, Canadian Association for the Study of the Liver

⚠ By 2030, the demand for #LiverDisease care will exceed the supply of #hepatology providers by more than 35%⚠   Faced with a critical shortage that could cripple access for thousands of patients, #hepatologists are urging their colleagues in #PrimaryCare and #gastroenterology to “start to own liver disease” and plug the anticipated gaps in chronic liver disease – notably, metabolic-dysfunction associated steatotic liver disease, hepatocellular carcinoma, #alcohol-associated liver disease and viral #hepatitis 📉   This month, Healio sat down with a roundtable of hepatologists who highlighted the crucial role #gastroenterologists can play in the care cascade ahead of the looming #shortage and how this crisis “should empower gastroenterologists to embrace their role in the management of chronic liver disease.” ➡ https://lnkd.in/gt7FWZem

World Liver Day is celebrated every year on 19 April to raise awareness and spread knowledge of chronic liver diseases, including Acute-on-Chronic Liver Failure (ACLF) a rapid-onset disease that currently has no approved treatments and is associated with a high mortality rate, up to 75% at 3 months. Our HepaStem® therapy, which is currently in clinical development stage, has the potential to allow recovery and regeneration of the body’s own liver cells and offers hope for the 100,000 patients who suffer from ACLF worldwide. Data from our recently completed phase II clinical trials is expected in H2 2024. 👉 Read the EASL | The Home of Hepatology fact sheet on ACLF: https://ibb.co/sbsG528 🔗 World Liver Day: https://lnkd.in/eKxD3-uF 🧪Learn how we are redefining liver treatments through cell therapies: www.cellaion.com #WorldLiverDay #StepUpForLiverHealth #Biotech #LiverFailure #UnmetMedicalNeed #ACLF